- The FMBA-developed mRNA vaccine showed 60–80% tumor reduction in preclinical trials.
- The first version of the vaccine will target colorectal cancer, with others in development for brain and skin cancers.
- The vaccine is customizable to each patient’s RNA and has proven safe for repeated use.
Russian researchers have developed a new cancer vaccine, which is now ready for clinical application, according to the Federal Medical-Biological Agency (FMBA). The declaration was issued by FMBA leader Veronika Skvortsova at the Eastern Economic Forum, according to a report from Russian news agency TASS.
The vaccine, named Enteromix, utilizes mRNA technology — the identical method employed in certain Covid-19 vaccines. Rather than utilizing a weakened virus, mRNA vaccines instruct the body’s cells to create proteins that activate an immune response targeting cancer cells.
Skvortsova mentioned that the vaccine has undergone years of research, incorporating three years of mandatory preclinical trials. The trials demonstrated that the vaccine remained safe even after multiple doses and was very effective. In certain instances, tumors decreased in size or progressed more slowly by 60% to 80%, depending on the cancer type.
Also Read: Takeda: Advancing Science to Transform Patient Outcomes
"The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced. FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully passed preclinical trials, demonstrating its safety and high effectiveness. The vaccine showed significant results in shrinking tumors and slowing their growth, and has also been found safe for repeated use. The vaccine will be customized for each patient, tailored to their individual RNA, Skvortsova said. She added that the first form of the vaccine will be used to treat colorectal cancer, while another version is in development for glioblastoma — a brain cancer — and specific types of melanoma, a skin cancer," Sputnik, a global wire and digital news service has posted on X.
Researchers observed enhanced survival rates in the test subjects. The initial emphasis for this vaccine will be on colorectal cancer, which pertains to cancer in the large intestine. Progress is being made on vaccines for glioblastoma, an aggressive brain cancer, and various forms of melanoma (a severe skin cancer), such as ocular melanoma, which impacts the eye.
The declaration was made at the 10th Eastern Economic Forum in Vladivostok, attracting over 8,400 attendees from more than 75 nations.